Drugs / Triiodothyronine (T3)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03787303 | Mar 2019 → Mar 2022 | breast cancer, thyroid gland disorder | Aultman Health Foundation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triiodothyronine (T3) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03787303 ↗ |
| Known as | liothyronine sodium | “Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.” NCT03787303 ↗ |
| Route | Oral | “Triiodothyronine (T3) tablets for oral administration” NCT03787303 ↗ |